Shore Capital Reiterates a Hold Rating on Taylor Wimpey PLC (LON:TW); Alimera Sciences, Inc. (ALIM) Covered By 3 Bullish Analysts Last Week

The stock rating of Taylor Wimpey PLC (LON:TW) was kept by investment analysts at Shore Capital. This was revealed in a research note on Wednesday, 7 February.

Among 3 analysts covering Alimera Sciences (NASDAQ:ALIM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera Sciences had 14 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, July 26. On Friday, September 16 the stock rating was upgraded by Cowen & Co to “Outperform”. The firm has “Buy” rating given on Tuesday, July 11 by Cowen & Co. Cowen & Co maintained it with “Buy” rating and $300 target in Thursday, August 3 report. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, January 19. The stock has “Buy” rating by H.C. Wainwright on Monday, January 22. The rating was maintained by Cowen & Co on Tuesday, July 25 with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $10 target in Wednesday, August 12 report. As per Wednesday, November 22, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 11. See Alimera Sciences, Inc. (NASDAQ:ALIM) latest ratings:

22/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
27/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
30/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $78.83 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

The stock decreased 0.87% or $0.01 during the last trading session, reaching $1.14. About 179,284 shares traded or 32.80% up from the average. Alimera Sciences, Inc. (NASDAQ:ALIM) has risen 0.67% since February 7, 2017 and is uptrending. It has underperformed by 16.03% the S&P500.

Investors sentiment increased to 1.64 in 2017 Q3. Its up 0.57, from 1.07 in 2017Q2. It increased, as 4 investors sold Alimera Sciences, Inc. shares while 7 reduced holdings. 8 funds opened positions while 10 raised stakes. 28.40 million shares or 11.41% more from 25.49 million shares in 2017Q2 were reported. Moreover, Armistice Ltd has 1% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). Two Sigma Secs Lc reported 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Bridgeway Cap Management Inc holds 0.01% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM) for 589,825 shares. Orbimed Advsr Ltd Liability, New York-based fund reported 250,000 shares. Weiss Multi reported 80,000 shares. Vanguard invested in 2.07 million shares. Guggenheim Cap Limited Com accumulated 18,995 shares or 0% of the stock. Deerfield Management holds 0.37% or 6.05M shares in its portfolio. Deutsche National Bank Ag reported 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Knott David M invested in 0.11% or 199,000 shares. Acuta Cap Prtnrs Ltd reported 974,318 shares or 0.24% of all its holdings. Barclays Public Limited Co, United Kingdom-based fund reported 93 shares. Millennium Mngmt Lc stated it has 21,809 shares. Jpmorgan Chase holds 27,500 shares or 0% of its portfolio. Centers Of America accumulated 24,000 shares or 0% of the stock.

Since January 16, 2018, it had 0 buys, and 10 insider sales for $313,603 activity. 14,494 shares were sold by EISWIRTH RICHARD S JR, worth $17,890 on Tuesday, January 16. Myers C. Daniel also sold $63,379 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) shares. 25,500 shares were sold by Ashman Philip, worth $31,475. Another trade for 25,500 shares valued at $30,552 was made by Holland David on Thursday, January 18. $14,181 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) shares were sold by Green Kenneth.

The stock increased 1.08% or GBX 2 during the last trading session, reaching GBX 186.75. About 4.79 million shares traded. Taylor Wimpey plc (LON:TW) has 0.00% since February 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 21 analysts covering Taylor Wimpey PLC (LON:TW), 12 have Buy rating, 1 Sell and 8 Hold. Therefore 57% are positive. Taylor Wimpey PLC has GBX 355 highest and GBX 140 lowest target. GBX 221.83’s average target is 18.78% above currents GBX 186.75 stock price. Taylor Wimpey PLC had 229 analyst reports since July 24, 2015 according to SRatingsIntel. JP Morgan maintained Taylor Wimpey plc (LON:TW) on Tuesday, November 15 with “Overweight” rating. Barclays Capital maintained it with “Equal Weight” rating and GBX 206.60 target in Friday, November 6 report. Deutsche Bank maintained the shares of TW in report on Friday, January 20 with “Buy” rating. As per Monday, February 1, the company rating was maintained by Liberum Capital. The firm has “Add” rating by Peel Hunt given on Wednesday, September 27. The stock of Taylor Wimpey plc (LON:TW) earned “Hold” rating by Deutsche Bank on Monday, February 6. As per Monday, June 20, the company rating was maintained by Deutsche Bank. As per Monday, July 31, the company rating was maintained by Deutsche Bank. Deutsche Bank maintained Taylor Wimpey plc (LON:TW) on Friday, February 19 with “Buy” rating. The stock of Taylor Wimpey plc (LON:TW) earned “Buy” rating by Deutsche Bank on Tuesday, November 8.

Taylor Wimpey plc operates as a homebuilding firm in the United Kingdom and Spain. The company has market cap of 6.10 billion GBP. It manufactures various homes, such as one- and two-bedroom apartments, and five-bedroom detached houses. It has a 11.39 P/E ratio.